absci.com (ABSI) - מזומני החברה

Absci is developing a scalable AI drug generation laboratory, monetizing licenses for pharmaceutical behemoths. The business relies on proprietary algorithms, delegating wet-lab testing to external CROs. Explosive growth in B2B contracts and royalties ensures the ecosystem's stability. The company's cash resource dynamics demonstrate its liquidity level, while 0.17 captures the current state of the free capital parameter.
Absci Corporation (ABSI) - פילוחי מדדים ודוחות פיננסיים

Investors assess fundamental capital risks by analyzing an issuer's ability to cover operating expenses without external borrowing. For Absci (ABSI), which is developing a B2B AI antibody generation ecosystem with a growing contract pipeline, financial autonomy is critical. The company's cash liquidity reflects its current cash reserves, allowing for a comparison of real business resilience against industry standards. Growth in this reserve confirms the safety of expansion, although excess funds may temporarily limit the overall return on invested capital.